Eurostars Grant for Novio Catalpa Consortium together with Medipan GmbH and Radboud University

The Novio Catalpa consortium has been selected as one of the 30 most promising innovations among all Eurostars submissions in 2025. The grant will be used to further develop our platform technology for the early diagnostics of autoimmune diseases. The initial application focuses on rheumatoid arthritis, a condition with high prevalence and growing relevance due to the development of new medicines that are most effective in the early stages of the disease.

Our test is a simple point-of-care solution based on the agglutination of blood, with the mediator dried on a diagnostic card. The Eurostars funding will support the further validation of the test, optimization of its stability in dried form, and preparation for market entry in full compliance with IVDR regulations.

In the consortium Novio Catalpa collaborates with the department of Biomolecular Chemistry of the Radboud University led by Prof. Ger Pruijn and Medipan GmbH in Germany.

Martin Salden, CEO Novio Catalpa BV:  “Receiving the Eurostars grant enables us to accelerate the validation of our technology and bring it to market sooner. This innovation allows for the early diagnosis of rheumatoid arthritis, with minimal barriers in terms of usability and cost. In addition, it provides valuable support for the development of new medicines. We are proud to have established a strong consortium that brings together the high-level scientific expertise of Radboud University and Medipan GmbH”.